deltatrials
Completed PHASE3 NCT00144482

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Sponsor: Chugai Pharmaceutical

Conditions Chemotherapy Induced Anemia
Interventions recombinant human erythropoietin recombinant human erythropoietin placebo
Updated 5 times since 2017 Last updated: Jan 29, 2009 Started: Dec 31, 2003 Primary completion: Mar 31, 2005 Completion: Aug 31, 2005

Listed as NCT00144482, this PHASE3 trial focuses on Chemotherapy Induced Anemia and remains completed. Sponsored by Chugai Pharmaceutical, it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chugai Pharmaceutical
Data source: Chugai Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.